Skip to content

Assessment of acceptance and self-assessment of a nasal spray

Assessment of acceptance in use and self-assessment of a nasal spray (094840-01) under normal conditions of use

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-5753p8c
Enrollment
Unknown
Registered
2023-02-05
Start date
2023-03-31
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhinitis

Interventions

Non-comparative clinical study. The evaluated health product is a Nasal Spray (0.04% sodium hyaluronate and 1% dexpanthenol solution). For this research, up to 37 participants aged 6 months to 2 years

Sponsors

Allergisa Pesquisa Dermato-Cosmetica Ltda
Lead Sponsor
Allergisa Pesquisa Dermato-Cosmetica Ltda
Collaborator
Megalabs Farmacêutica S.A.
Collaborator

Eligibility

Age
6 Months to 3 Years

Inclusion criteria

Inclusion criteria: Healthy pediatric subjects; Intact skin on test site; Agreement of the child's legal guardian to adhere to the procedures and requirements of the study and to report to the institute on the day(s) and at the time(s) scheduled for the assessments; Ability by the guardian of consenting to the participation of the child in the study; Children aged from 6 months to 2 years and 11 months; Study subjects of any gender. Subjects presenting phototype (Fitzpatrick) I to IV;Users of products of the same category.

Exclusion criteria

Exclusion criteria: Skin pathology on the area of product application; Diabetes; Immunological insufficiency.Current use of the following topical or systemic medications: corticosteroids, immunosuppressant and anti-histaminic drugs.Skin diseases: vitiligo, psoriasis, atopic dermatitis; History of reaction to the category of product tested; Other diseases or medications that might directly interfere with the study or put subject's health under risk.

Design outcomes

Primary

MeasureTime frame
It is expected that the application of the product does not promote the appearance of adverse events and sensations of discomfort in the nasal mucosa when used under normal conditions of use, based on evaluations with the dermatologist and otorhinolaryngologist after 30 days (T30) of daily use of the product. Exploratory data analysis will be performed (summary tables and graphs). The comparison of the T30 time in relation to the initial time (T0) will be performed using Student's t test, with a confidence level of 95%.

Secondary

MeasureTime frame
Improvement in wetting, hydration, fluidization and hygiene of the nasal mucosa evaluated from the completion of the Perceived Efficacy Questionnaire after the last application of the product at home by the research participants' guardians, descriptions in the participant's diary and medical evaluations after 30 days of daily use of the product. Exploratory data analysis will be performed (summary tables and graphs). The comparison of the T30 time in relation to the initial time (T0) will be performed using Student's t test, with a confidence level of 95%.;It is expected that the application of the product does not cause the appearance of adverse events and sensations of discomfort in the nasal mucosa when used under normal conditions of use, based on evaluations with the pediatrician after 30 days (T30) of daily use of the product. Exploratory data analysis will be performed (summary tables and graphs). The comparison of the T30 time in relation to the initial time (T0) will be performed using Student's t test, with a confidence level of 95%.

Countries

Brazil

Contacts

Public ContactMariane Martins

Allergisa Pesquisa Dermato-Cosmetica Ltda

marianem@allergisa.com.br+55 (19) 3789-8600

Outcome results

None listed

Source: REBEC (via WHO ICTRP)